

Omi Parikh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9183411/publications.pdf>

Version: 2024-02-01

5
papers

3,122
citations

1684188

5
h-index

2053705

5
g-index

5
all docs

5
docs citations

5
times ranked

3727
citing authors

#	ARTICLE	IF	CITATIONS
1	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	13.7	1,570
2	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	27.0	1,315
3	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
4	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	8.4	35
5	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29